Christopher P. Venner

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Thierry Façon, Shaji Kumar, Torben Plesner et al. · New England Journal of Medicine · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema et al. · New England Journal of Medicine · 2021 · 668 citations · Full text

Life Sciences, Hematology, Pharmacology +15

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome

Jennifer H. Pinney, Carol Whelan, Aviva Petrie et al. · Journal of the American Heart Association · 2013 · 378 citations · Full text

Medicine, Cardiology, Internal Medicine +11

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Thierry Façon, Shaji Kumar, Torben Plesner et al. · The Lancet Oncology · 2021 · 363 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 324 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16